Fampridine Intoxication : Case Report

Year 2022, Volume: 4 Issue: 2, 51 - 53, 30.08.2022

İlkay Türköz , Melih Emre Bacanak , Pınar Karabacak , Hacı Ömer Osmanlıoğlu , Mustafa Soner Özcan , Eyyüp Sabri Özden

https://doi.org/10.51262/ejtox.1092277

Abstract

Fampridine, (4 AP, 4-Aminopyridine, dalfampridine) is a drug that acts by blocking potassium channels and is effective in nerve damage. It is used in the treatment of diseases such as multiple sclerosis (MS), spinal cord injuries, Lambert-Eaton syndrome and myasthenia gravis. There are very few cases of fampridine toxicity in the literature. There is no antidote treatment for toxic intakes of this drug, which has very serious side effects, but symptomatic treatment should be started early.
Here, a case followed in the intensive care unit with fampridine toxicity is presented.

Keywords

Fampridine, Multiple sclerosis, Intoxication

Fampridin İntoksikasyonu: Olgu Sunumu

Abstract

Fampridine, (4-AP, 4-Aminopiridin dalfampridine), potasyum kanallarını bloke ederek etki eden ve sinir hasarında etkili olan bir
ilaçtır. Multipl skleroz (MS), omurilik yaralanmaları, Lambert-Eaton sendromu ve miyastenia gravis gibi hastalıkların tedavisinde kullanılmaktadır.
Literatürde fampiridin toksisitesine yönelik oldukça az sayıda olgu bulunmaktadır. Oldukça ciddi yan etkileri olan bu ilacın toksik alımlarında antidot
tedavi bulunmamaktadır fakat semptomatik tedaviye erken başlanmalıdır. Burada fampridin toksisitesi ile yoğun bakımda takip edilen bir
olgu sunulmuştur.

Keywords

Fampridine, Multipl skleroz, İntoksikasyon

References

• Yamout BI, Alroughani R. Multiple Sclerosis. Semin Neurol. 2018 Apr;38(2):212-225. doi: 10.1055/s-0038-1649502. Epub 2018 May 23. PMID: 29791948.
• Katz Sand, Ilana Multipl sklerozun 3ması, Cilt ve görüş muayene, Nörolojide Güncel: Haziran 2015 - Cilt ve Görüş muayenesi, Haziran 2015 - s 193-205 doi: 10.1097/WCO.0000000000000206
• Hart FM, Bainbridge J. Current and emerging treatment of multiple sclerosis. Am J Manag Care. 2016 Jun;22(6 Suppl):s159-70. PMID: 27356025.
• Keogh M, Sedehizadeh S, Maddison P. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev. 2011 Feb 16;2011(2):CD003279. doi: 10.1002/14651858.CD003279.pub3. PMID: 21328260; PMCID: PMC7003613.
• Dilek F, Bitek DE, Erol Ö, Ünsar S. Multipl Skleroz’da Üç Semptom Ve Hemşirelik Yönetimi: Yorgunluk, Mesane Problemleri, Cinsellik. Anadolu Hemşirelik ve Sağlık Bilimleri Dergisi 2019; 22(4): 300-5.
• McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7.
• Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 2018;24:96-120.
• Husseini L, Leussink VI, Kieseier BC, Hartung HP. 4-Aminopyridin (Fampridin). Ein neuer Ansatz zur symptomatischen Therapie der Multiplen Sklerose [4-Aminopyridine (Fampridine). A new attempt for the symptomatic treatment of multiple sclerosis]. Nervenarzt. 2010 Feb;81(2):203-11. German. doi: 10.1007/s00115-009-2902-2. PMID: 20112006.
• Schwam E. Severe accidental overdose of 4-aminopyridine due to a compounding pharmacy error. J Emerg Med. 2011 Jul;41(1):51-4. doi: 10.1016/j.jemermed.2009.04.037. Epub 2009 May 13. PMID: 19443164.
• Fil LJ, Sud P, Sattler S. A Massive Overdose of Dalfampridine. West J Emerg Med. 2015 Dec;16(7):1177-9. doi: 10.5811/westjem.2015.8.26127. Epub 2015 Dec 3. PMID: 26759675; PMCID: PMC4703168.
• King AM, Menke NB, Katz KD, Pizon AF. 4-aminopyridine toxicity: a case report and review of the literature. J Med Toxicol. 2012 Sep;8(3):314-21. doi: 10.1007/s13181-012-0248-9. PMID: 22782458; PMCID: PMC3550165.
• King AM, Menke NB, Katz KD, Pizon AF. 4-aminopyridine toxicity: a case report and review of the literature. J Med Toxicol. 2012 Sep;8(3):314-21. doi: 10.1007/s13181-012-0248-9. PMID: 22782458; PMCID: PMC3550165